Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Adjuvant Cetuximab in Advanced Tongue Cancer
NCT01760811Phase 2Unknown
- Sponsor
- Rabin Medical Center
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in squamous cell carcinoma of the tongue (TSCC), sponsored by Rabin Medical Center. Status: unknown.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the tongue (TSCC)
Beyond the preview
Go deeper on NCT01760811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760811.